Abstract
The decision making in patients with an atrial septal defect (ASD) in setting of pulmonary hypertension is complex. In the era of pulmonary arterial vasodilator therapy, every patient should undergo evaluation by pulmonary hypertension experts especially if defect closure is being considered. Defect closure in the inappropriate group can lead to poor outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | e602-e605 |
Journal | American journal of therapeutics |
Volume | 24 |
Issue number | 5 |
DOIs | |
State | Published - 2017 |
Externally published | Yes |
Keywords
- Amplatzer septal occluder
- ASD
- Eisenmenger physiology
- pulmonary hypertension
- pulmonary-to-systemic flow (Qp/Qs) ratio
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)